Cryoport (CYRX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $56.7 million, up 1% year-over-year, driven by 9% growth in Life Sciences Services and offset by a 13.7% decline in Life Sciences Products revenue.

• Life Sciences Services revenue grew 9% in Q3, with BioStorage/BioServices up over 12% year-over-year.

• Supported a record 691 global clinical trials as of September 30, 2024, including 79 in Phase III, and 17 commercial therapies.

• Cost reduction and realignment strategies are on track, improving gross margin, adjusted EBITDA, and cash flow.

• Launched IntegriCell Cryopreservation Solution and opened a new Houston facility in October.

Financial highlights

• Gross margin for Q3 2024 improved to 44.8% (Life Sciences Services: 46.0%), up from 43.2% in Q3 2023.

• Adjusted EBITDA for Q3 2024 was negative $2.4 million, an improvement from negative $3.1 million in Q3 2023.

• Net income for Q3 2024 was $0.8 million, compared to a net loss of $13.3 million in Q3 2023, aided by a $17.3 million gain on extinguishment of debt.

• Cash, cash equivalents, and short-term investments totaled $272.7 million as of September 30, 2024.

• Life Sciences Products revenue declined 14% year-over-year in Q3 2024.

Outlook and guidance

• Full-year 2024 revenue guidance reaffirmed at $225–$235 million.

• Management expects continued growth in services and a return to positive adjusted EBITDA during 2025.

• Ongoing softness in product sales and macro/sector-specific challenges expected to persist.

• Current liquidity and projected cash flows are expected to satisfy operational and capital requirements for at least the next twelve months.